Akèy › Leksemi mieloïd egi › Minnesota › Minneapolis
Etid klinik pou Leksemi mieloïd egi nan Minneapolis, MN
20 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Minneapolis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Ap rekriteFaz 1
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Masonic Cancer Center, Minneapolis
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- University of Minnesota, Minneapolis
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Ap rekriteFaz 1/2
- Masonic Cancer Center, Minneapolis
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Ap rekriteFaz 1
- Masonic Cancer Center, Minneapolis
Allo HSCT Using RIC and PTCy for Hematological Diseases
Ap rekriteFaz 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Ap rekriteFaz 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Ap rekriteFaz 1/2
- Mark Juckett, MD, Minneapolis
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Ap rekriteFaz 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
Ap rekriteEtid obsèvasyon
- University of Minnesota/Masonic Cancer Center, Minneapolis
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Ap rekriteFaz 2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- University of Minnesota, Minneapolis
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Minneapolis
- Kansè nan tete27 etid
- Kansè Poumon ki pa ti selil26 etid
- Kansè ovè24 etid
- Kansè pwostat23 etid
- Kansè (tout kalite)22 etid
- Ensifizyans kadyak21 etid
- Kansè poumon20 etid
- Kansè kolorektal19 etid
- Kansè Endomèt18 etid
- Maladi Parkinson17 etid
- Maladi kadyovaskilè15 etid
- Maladi atè koronè13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.